Steven R Feldman
Wake Forest University Health Sciences · Wake Forest University Health Science · Wake Forest University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Steven R Feldman as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:28 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT07661979 · Opzelura Experience StudyWake Forest University Health Sciences · not yet recruiting · Atopic Dermatitis · principal investigator
- N/ANCT07391423 · Assessing Psoriasis Treatment OutcomesWake Forest University Health Sciences · not yet recruiting · Psoriasis · principal investigator
- N/ANCT06244212 · Topical Treatment for Atopic DermatitisWake Forest University Health Sciences · recruiting · Atopic Dermatitis · principal investigator
- Ph2/Ph3NCT05981118 · Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)Wake Forest University Health Sciences · enrolling by invitation · ICD10 Code L40.9 for Psoriasis · principal investigator
- Early Ph1NCT05601492 · Adherence to OtezlaWake Forest University Health Sciences · withdrawn · Psoriasis · principal investigator
- Early Ph1NCT05582434 · Experience With Topical Acne TreatmentWake Forest University Health Sciences · active not recruiting · Acne · principal investigator
- N/ANCT05570955 · Deucravacitinib Adherence StudyWake Forest University Health Sciences · active not recruiting · Psoriasis · principal investigator
- N/ANCT04341623 · Xerosis and Use of Topical MoisturizerWake Forest University Health Sciences · active not recruiting · Xerosis Due to Atopic Dermatitis · principal investigator
- Ph2NCT04275999 · Rosacea and IvermectinWake Forest University Health Sciences · completed · Rosacea · principal investigator
- N/ANCT04058652 · Use of Transcutaneous Electrical Nerve Stimulation for Reducing Biologic Injection Site Pain(TENS Study)Wake Forest University Health Sciences · active not recruiting · Psoriasis · principal investigator
- Early Ph1NCT03979664 · Iontophoresis in PsoriasisWake Forest University Health Sciences · withdrawn · Psoriasis, Psoriasis Vulgaris, Skin Diseases · principal investigator
- N/ANCT03572738 · Hidradenitis Suppurativa Mail SurveyWake Forest University Health Sciences · completed · Hidradenitis Suppurativa · principal investigator
- N/ANCT03465696 · A Priming Intervention to Increase Patient Willingness to Use Injectables for the Management of PsoriasisWake Forest University Health Sciences · completed · Psoriasis · principal investigator
- N/ANCT03049319 · MED in UVB Devices in the Presence and Absence of UV FilterWake Forest University Health Sciences · withdrawn · Healthy Participants and/or Patients · principal investigator
- Early Ph1NCT01802580 · Using an Internet Study to Improve Adherence for Psoriasis PatientsWake Forest University · completed · Psoriasis · principal investigator
- Ph4NCT01504204 · Effect of Samples on Acne Treatment With Epiduo® GelWake Forest University · completed · Acne Vulgaris · principal investigator
- Ph2NCT01469767 · Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic DermatitisWake Forest University · completed · Atopic Dermatitis · principal investigator
- N/ANCT01444989 · Development and Validation of a Quality of Life Instrument for Actinic KeratosisWake Forest University · completed · Actinic Keratosis · principal investigator
- N/ANCT01435265 · Nurse Education in Subjects With Psoriasis Undergoing Treatment With AdalimumabWake Forest University Health Sciences · completed · Psoriasis · principal investigator
- N/ANCT01385527 · Pediatric Atopic Dermatitis (AD) Internet SurveyWake Forest University · withdrawn · Atopic Dermatitis · principal investigator
- N/ANCT01176955 · A Novel Method to Improve Acne OutcomesWake Forest University · completed · Acne Vulgaris · study director
- Ph4NCT01047189 · Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne VulgarisWake Forest University · completed · Acne Vulgaris · principal investigator
- Ph2NCT00713349 · Controlled Study of the Effect of Xenaderm® Ointment Vehicle Versus White Petrolatum on HealingHealthpoint · completed · Wounds · principal investigator
- Ph4NCT00658112 · Measuring Adherence in Subjects With Acne Vulgaris in a Clinic Population Subtitle: Topical Benzoyl Peroxide for AcneWake Forest University · completed · Acne Vulgaris · principal investigator
- N/ANCT00447083 · Benefits of Tanning in Fibromyalgia PatientsWake Forest University · completed · Fibromyalgia Syndrome · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:28 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Recruiting Rural Parents/Infants to Health Research Projects: Atopic DermatitisR21AI070687 · NIAID · WAKE FOREST UNIVERSITY HEALTH SCIENCES · fiscal years 2009 to 2010 · $185,000 awarded in 2010Same name and institution; not confirmed by an ID
- REINFORCING PROPERTIES OF UV LIGHT IN TANNING BED USERSM01RR007122 · NCRR · WAKE FOREST UNIVERSITY HEALTH SCIENCES · fiscal years 1998 to 2005 · $847 awarded in 2005Same name and institution; not confirmed by an ID
- Hawthorne Conference on Office-Based SurgeryR13AR048197 · NIAMS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · fiscal years 2001 · $2,000 awarded in 2001Same name and institution; not confirmed by an ID
- Reinforcing Properties of UV Light in Tanning Bed UsersR03DA014014 · NIDA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · fiscal years 2001 · $72,188 awarded in 2001Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:28 UTC. The ranking covers the 200 most relevant of 118 PubMed records, and a shared surname and initials can bring in a namesake. All 118 on PubMed
- A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.J Am Acad Dermatol · 2007376 citationsRCR 11.7
- Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.Br J Dermatol · 2015265 citationsRCR 9.8
- Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.J Am Acad Dermatol · 2010174 citationsRCR 5.4
- Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.J Am Acad Dermatol · 2005173 citationsRCR 4.0
- Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: commonly used methods of measuring adherence to topical therapy overestimate actual use.J Am Acad Dermatol · 2004164 citationsRCR 6.5
- Adherence to topical therapy increases around the time of office visits.J Am Acad Dermatol · 2007123 citationsRCR 5.2
- Tacrolimus ointment is effective for facial and intertriginous psoriasis.J Am Acad Dermatol · 2004121 citationsRCR 4.4
- Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study.J Allergy Clin Immunol · 2021120 citationsRCR 8.0
- Better medication adherence results in greater improvement in severity of psoriasis.Br J Dermatol · 2004106 citationsRCR 4.2
- Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.Br J Dermatol · 2005106 citationsRCR 3.5